Insights

Industry Focus Flash BioSolutions operated within the biopharmaceutical manufacturing sector, specifically specializing in lentiviral vector design and bioproduction for gene, cell, RNA, and vaccine therapies, highlighting opportunities to partner with biotech firms focused on gene editing and personalized medicine.

Recent Leadership Change The appointment of Jérôme Bédier as President in mid-2023 indicates strategic leadership changes, potentially opening doors for collaborations or sales initiatives around advanced gene therapy solutions and bioproduction services.

Innovative Pipeline With plans to produce the first clinical batch of LentiFlash messenger RNA by the end of 2022, the company demonstrated ongoing innovation in mRNA therapeutics, presenting sales prospects in clinical-stage biotech and pharmaceutical firms seeking novel gene transfer technologies.

Funding & Growth Potential Having secured €3.3 million in initial investment and a total funding of $18 million, Flash BioSolutions shows strong backing for growth and development, indicating a market opportunity for suppliers of biotech equipment, reagents, and manufacturing support tailored to expanding gene therapy startups.

Market Positioning Despite its small size with fewer than 50 employees and modest revenue, the company's engagement in cutting-edge gene and RNA therapy development positions it as a potential early adopter or strategic partner for companies providing advanced bioproduction technologies and clinical development services in the gene therapy space.

Flash BioSolutions Tech Stack

Flash BioSolutions uses 8 technology products and services including Linkedin Insight Tag, jQuery, HubSpot, and more. Explore Flash BioSolutions's tech stack below.

  • Linkedin Insight Tag
    Analytics
  • jQuery
    Javascript Libraries
  • HubSpot
    Marketing Automation
  • PWA
    Miscellaneous
  • Priority Hints
    Performance
  • PHP
    Programming Languages
  • Yoast SEO
    Search Engines
  • Autoptimize
    Web Platform Extensions

Media & News

Flash BioSolutions's Email Address Formats

Flash BioSolutions uses at least 1 format(s):
Flash BioSolutions Email FormatsExamplePercentage
First.Last@flashtherapeutics.comJohn.Doe@flashtherapeutics.com
50%
First.Last@flashtherapeutics.comJohn.Doe@flashtherapeutics.com
50%

Frequently Asked Questions

What is Flash BioSolutions's official website and social media links?

Minus sign iconPlus sign icon
Flash BioSolutions's official website is flashtherapeutics.com and has social profiles on LinkedInCrunchbase.

What is Flash BioSolutions's NAICS code?

Minus sign iconPlus sign icon
Flash BioSolutions's NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does Flash BioSolutions have currently?

Minus sign iconPlus sign icon
As of December 2025, Flash BioSolutions has approximately 18 employees across 1 continents, including Europe. Key team members include Business & Marketing Director: A. D.Biosafety Officer & Cmc Lead: L. L.Cell Engineering Project Manager: F. S.. Explore Flash BioSolutions's employee directory with LeadIQ.

What industry does Flash BioSolutions belong to?

Minus sign iconPlus sign icon
Flash BioSolutions operates in the Pharmaceutical Manufacturing industry.

What technology does Flash BioSolutions use?

Minus sign iconPlus sign icon
Flash BioSolutions's tech stack includes Linkedin Insight TagjQueryHubSpotPWAPriority HintsPHPYoast SEOAutoptimize.

What is Flash BioSolutions's email format?

Minus sign iconPlus sign icon
Flash BioSolutions's email format typically follows the pattern of First.Last@flashtherapeutics.com. Find more Flash BioSolutions email formats with LeadIQ.

How much funding has Flash BioSolutions raised to date?

Minus sign iconPlus sign icon
As of December 2025, Flash BioSolutions has raised $18M in funding. The last funding round occurred on Aug 07, 2021 for $18M.

When was Flash BioSolutions founded?

Minus sign iconPlus sign icon
Flash BioSolutions was founded in 2005.

Flash BioSolutions

Pharmaceutical ManufacturingOccitanie, France11-50 Employees

It is with deep regret that we announce the liquidation of FlashTherapeutics and the end of its activities.
Over the years, FlashTherapeutics has been driven by the ambition to innovate and bring transformative solutions to patients. This journey would not have been possible without the dedication of our talented team, the trust of our partners and clients, and the unwavering support from all those who believed in our mission.
We want to warmly thank all employees, collaborators, and stakeholders who contributed to this adventure. Your commitment, creativity, and passion have left a lasting mark.
Although FlashTherapeutics’ path comes to an end, we are confident that the science, partnerships, and expertise that emerged along the way will continue to live on through those who pursue innovation and progress in the service of patients.
We remain proud of our collective achievements and humbled by the privilege of having contributed, even in part, to the advancement of healthcare solutions.
To everyone who walked with us on this journey: thank you.

Section iconCompany Overview

NAICS Code
3254 - Pharmaceutical and Medicine Manufacturing
Founded
2005
Employees
11-50

Section iconFunding & Financials

  • $18M

    Flash BioSolutions has raised a total of $18M of funding over 2 rounds. Their latest funding round was raised on Aug 07, 2021 in the amount of $18M.

  • $1M

    Flash BioSolutions's revenue is estimated to be in the range of $1M

Section iconFunding & Financials

  • $18M

    Flash BioSolutions has raised a total of $18M of funding over 2 rounds. Their latest funding round was raised on Aug 07, 2021 in the amount of $18M.

  • $1M

    Flash BioSolutions's revenue is estimated to be in the range of $1M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.